ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

ClinicalTrials.gov ID: NCT02308020

Public ClinicalTrials.gov record NCT02308020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma

Study identification

NCT ID
NCT02308020
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
162 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 19, 2015
Primary completion
Nov 7, 2018
Completion
Nov 7, 2019
Last update posted
Dec 18, 2020

2015 – 2019

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
City of Hope National Medical Center Duarte California 91010
University of California - San Diego La Jolla California 92037-0845
Univ of California San Francisco San Francisco California 94115
John Wayne Cancer Institute Santa Monica California 90404
University of Colorado Aurora Colorado 80045
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Florida Cancer Specialists Fort Myers Florida 33916-2233
H Lee Moffitt Cancer Center Tampa Florida 33612-9497
Kaiser Permanente Center for Health Research Honolulu Hawaii 96819
James Graham Brown Cancer Center Louisville Kentucky 40202
Dana Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Ann Arbor Michigan 48109
Washington University Medical Center St Louis Missouri 63110
Memorial Sloan Kettering Cancer Center New York New York 10065
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599
Providence Health and Services Portland Oregon 97213
SMO Sarah Cannon Research Inst. Nashville Tennessee 37203
Tennessee Oncology PLLC Nashville Tennessee 37203
University of Texas MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02308020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02308020 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →